Table 2 Baseline (at the initiation of TDF treatment) characteristics of the 103 patients stratified by significant liver stiffness regression achievement after 90 (range: 36–154) months TDF monotherapy

Age, years*

> 60 years old, n (%)

57 ± 13

16 (47%)

55 ± 14

28 (40%

0.5

0.6

Male patients, n (%)

18 (53%)

40 (58%)

0.6

HBeAg– positive, n (%)

3 (10%)

5 (7%)

0.7

Baseline liver stiffness (kPa)*

10 ± 7

8 ± 5

0.01

Advanced fibrosis/cirrhosis

Cirrhosis n (%)

14 (40%)

8 (23%)

11 (16%)

6 (9%)

0.02

0.09

Treatment duration with TDF*, months

79 ± 26

79 ± 27

0.9

ALT (IU/L)**

ALT > 40 IU/mL, n (%)

43 (14–458)

17 (50%)

30 (11-2130)

31 (45%)

0.3

0.7

HBV DNA (log₁₀ IU/L)**

4.9 (2.7–7.4)

4.7 (2.3–8.8)

0.7

Platelet x 10⁹ /L**

196 (61–337)

204 (68–334)

0.06

BMI (Kg/m²)*

≥ 25Kg/m², n (%)

≥ 30 Kg/m², n (%)

24 ± 5

1 (3%)

0

27 ± 3

45 (65%)

10 (14%)

0.001

< 0.001

0.09

Diabetes Mellitus, n (%)

3 (8%)

7 (10%)

1

Hypertension, n (%)

14(41%)

15(21%)

0.1

Dyslipidemia, n (%)

1 (3.7%)

10 (15%)

0.3

Parameters of metabolic syndrome, n (%)

17 (50%)

30 (43%)

0.6

Active smokers, n (%)

9 (25%)

12 (18%)

0.6